China Metformin Market Investigation Report 2021-2025

0

Dublin, December 31, 2021 (GLOBE NEWSWIRE) – The “China Metformin Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.com offer.

The analyst expects that with the relief of COVID-19, the sales value of metformin in the Chinese market will see restorative growth from 2021 to 2025.

According to the analyst’s market research, the sales value of metformin in the Chinese market has increased year on year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the whole diagnostic and medical treatment services, the sales value of metformin in the Chinese market fell to CNY 707 million in 2020, down 4.19% year-on-year. The sales value CAGR of metformin in the Chinese market from 2016 to 2020 is 7.01%.

Metformin is the first-line drug for the treatment of type 2 diabetes, especially in people who are overweight. Metformin was originally developed by Merck Sharp & Dohme (trade name: GLUCOPHAGE).

GLUCOPHAGE was first marketed in France in 1957 and in China in 1994. Since then, some generic drugs have also been listed on the Chinese market. According to the analyst’s market research, there are several manufacturers in the Chinese metformin market by 2020, including the Chinese-American Shanghai Squibb Pharmaceutical Co., Ltd. represents the largest market share.

In addition, the number of diabetic patients in China ranks first in the world. The total prevalence rate of diabetes in adults is 12.8%. Type II diabetes represents 90% of diabetic patients, and the number of patients is enormous. At the same time, as the aging of the population in China becomes more and more severe, the number of patients and the prevalence rate are also increasing year by year.

Therefore, the sales volume and the sales value of metformin for the treatment of type 2 diabetes are trending upward. In addition, compared to similar drugs, metformin not only has the effect of lowering blood sugar, but may also have the effect of losing weight and treating hyperinsulinemia, and it may be effective for patients with severe blood sugar. low efficacy of some sulfonylureas. Based on these advantages, the sales value of metformin in the Chinese market is expected to increase from 2021 to 2025.

Topics covered:

  • The impact of COVID-19 on the Chinese metformin market
  • 2016-2020 Chinese Metformin Sales Value
  • Competitive Landscape of the Chinese Metformin Market
  • Metformin Price in China
  • China Metformin Price by Regions and Manufacturers
  • Analysis of Factors Affecting the Development of China Metformin Market
  • China Metformin Market Outlook 2021-2025

Main topics covered:

1 Relevant concepts of metformin
1.1 Indications for metformin
1.2 Development of metformin in China
1.3 Government approval of metformin in China
1.4 The impact of COVID-19 on metformin sales in China

2 China Metformin Sales, 2016-2020
2.1 Sales value of metformin
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Metformin Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Metformin Sales by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Prolonged-release tablets
2.3.3 Prolonged-release capsules
2.3.4 Enteric coated tablets
2.3.5 Enteric coated capsules

3 China Major Manufacturers Analysis of Metformin, 2016-2020
3.1 Major Manufacturers of Metformin Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 The Sino-American Shanghai Squibb Pharmaceutical Ltd.
3.2.1 Company profile
3.2.2 Sales of GLUCOPHAGE (Metformin of Sino-US company Shanghai Squibb Pharmaceutical Ltd.) in China
3.3 Merck Santé SA
3.3.1 Company profile
3.3.2 Sales of GLUCOPHAGE (Metformin by Merck Santé SA) in China
3.4 Chongqing Kangker Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Dulening (Chongqing Kangker Pharmaceutical Co., Ltd.) Metformin in China
3.5 Beijing Shengyong Pharmaceutical Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Junlida (Beijing Shengyong Pharmaceutical Co., Ltd.) Metformin in China
3.6 Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. Metformin Sales in China

4 Metformin Price for Different Manufacturers in China, 2020-2021
4.1 The Sino-American Shanghai Squibb Pharmaceutical Ltd. (GLUCOPHAGE)
4.2 Merck Santé SA (GLUCOPHAGE)
4.3 Chongqing Kangker Pharmaceutical Co., Ltd. (Dulening)
4.4 Beijing Shengyong Pharmaceutical Co., Ltd. (Junlida)
4.5 Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.

5 China Metformin Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese Metformin Market
5.1.1 The impact of COVID-19 on the Chinese metformin market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/gau6jn


        
Share.

Comments are closed.